The Effects of Inhaled Terbutaline on 3-km Running Time-Trial Performance

The Effects of Inhaled Terbutaline on 3-km Running Time-Trial Performance / John Molphy, John W. Dickinson, Neil J. Chester, Mike Loosemore, Gregory Whyte. - (International journal of sports physiology and performance (2018, 20 Dec) p. 1-26).
- PMID: 30569748.
- DOI: 10.1123/ijspp.2018-0633


To investigate the effects of two therapeutic (2mg; 4mg) inhaled doses of terbutaline on 3km running time-trial performance.

Eight males (24.3±2.4yrs; 77.6±8kg; 179.5±4.3cm) and eight females (22.4±3yrs; 58.6±6kg; 163±9.2cm) free from respiratory disease and illness provided written informed consent. Participants completed 3 km running time-trials on a non-motorised treadmill on three separate occasions following placebo, 2 mg or 4 mg inhaled terbutaline, in a single-blind, repeated-measures design. Urine samples (15mins post-exercise) were analysed for terbutaline concentration. Data were analysed using one-way repeated measures ANOVA, significance was set at p<0.05 for all analyses.

No differences were observed for completion times (1103±201; 1106±195; 1098±165s; P=0.913) for the placebo trial, the 2mg inhaled trial and the 4mg inhaled trial, respectively. Lactate values were higher (P=0.02) following 4mg terbutaline (10.7±2.3mmol·L-1) vs. placebo (8.9±1.8mmol·L-1). FEV1 values were greater following inhalation of 2mg (5.08±0.2; P=0.01) and 4mg terbutaline (5.07±0.2; P=0.02) compared to placebo (4.83±0.5L) post-inhalation. Urinary terbutaline concentrations were mean (306±288ng·mL-1; 435±410ng·mL-1; P=0.2) and peak (956ng·mL-1; 1244ng·mL-1) following 2mg and 4mg inhaled terbutaline, respectively. No differences were observed between the male and female participants.

Therapeutic dosing of terbutaline does not lead to an improvement in 3 km running performance despite significantly increased FEV1. Our findings suggest that athletes using inhaled terbutaline at high therapeutic doses to treat asthma will not gain an ergogenic advantage during 3 km running performance.


Research / Study
20 December 2018
Chester, Neil J.
Dickinson, John W.
Loosemore, Mike
Molphy, John
Whyte, Gregory
United Kingdom
Other organisations
Liverpool John Moores University (LJMU)
University College London (UCL)
University of Kent
Doping classes
S3. Beta-2 Agonists
Medical terms
Substance use research
Therapeutic Use Exemption (TUE)
Doping control
Document category
Date generated
17 January 2019
Date of last modification
19 February 2019
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period